Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?

Nature Clinical Practice Oncology volume 4, pages 460–461 (2007)Cite this article

boxed-textOettle H et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267–277

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Bakkevold KE et al. (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29: 698–703

    Article  Google Scholar 

  2. Takada T et al. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95: 1685–1695

    Article  Google Scholar 

  3. Kosuge T et al. (2006) A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 36: 159–165

    Article  Google Scholar 

  4. Neoptolemos JP et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200–1210

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice. The author wishes to thank Dr Franck Bonnetain (Fédération Française de Cancérologie Digestive) for his assistance with statistical analyses.

Author information

Author notes

  1. Pôle des Maladies, de l'Appareil Digestif, Hôpital Beaujon, 100 Boulevard Leclerc, 92110 Clichy, France pascal.hammel@bjn.aphp.fr

Affiliations

  1. P Hammel is a Professor of Gastroenterology in the Department of Hepatogastroenterology at the Beaujon Hospital, Clichy, France.

    Pascal Hammel

Authors
  1. Pascal Hammel
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hammel, P. Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?. Nat Rev Clin Oncol 4, 460–461 (2007). https://doi.org/10.1038/ncponc0884

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0884

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing